Since CTLA-4 and PD-1 negatively affect proliferation and cytotoxicity of CTLs and, at the same time, promote the generation and immunosuppressive properties of Tregs in irradiated tumours, the use of monoclonal antibodies, which induce a blockade of CTLA-4 (Ipilimumab) and PD-1 (Nivolumab and Pembrolizumab) opened a completely new avenue in cancer RT (reviewed by Demaria et al. [71] and Wang et al. [72]). Here, CTLA4 is linked to neoplasm.